SCHEMBL16203602

SCHEMBL16203602

C[C@@H]1[C@H](OC(=O)c2ccccc2)[C@H](n2cnc3c(NC(=O)c4ccccc4)ncnc32)O[C@@H]1CO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.53
ADORA1 P30542 6/20 0.51
P2RX3 P56373 1/20 0.51
P2RX4 Q99571 1/20 0.51
P2RX2 Q9UBL9 1/20 0.51
ADORA3 P0DMS8 3/20 0.49
LMNA P02545 2/20 0.49
ADORA2A P29274 2/20 0.49
ADORA2B P29275 2/20 0.49
SLC29A1 Q99808 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GLA P06280 1/20 0.49
PMP22 Q01453 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 1/20 0.49
NPY1R P25929 1/20 0.49
HTT P42858 1/20 0.49
NPY2R P49146 1/20 0.49
RAB9A P51151 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26808451 0.93 PRMT6 (0.53) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL25505237 0.93 PRMT6 (0.53) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL11685620 0.92 PRMT6 (0.57) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL13020687 0.92 PRMT6 (0.57) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL16206177 0.92 PRMT6 (0.57) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL29672351 0.92 PRMT6 (0.57) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL18464846 0.91 PRMT6 (0.53) PRMT6ADORA1ADORA3LMNAADORA2A
SCHEMBL26553789 0.91 PRMT6 (0.53) PRMT6ADORA1ADORA3LMNAADORA2A
SCHEMBL19780104 0.91 PRMT6 (0.55) PRMT6ADORA1P2RX3P2RX4P2RX2
SCHEMBL19777693 0.91 PRMT6 (0.55) PRMT6ADORA1P2RX3P2RX4P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181294-B2 Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2015-11-10 US disclosed
US-20140323425-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323425-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT SAMHD1, NUDT1, TYMP PRMT6 1678/4885ADORA1 316/4885P2RX3 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.